drugset / Trial / NCT03669601

AZD6738 & Gemcitabine as Combination Therapy

NCT03669601

Phase 1 Unknown 55 enrolled CCTU- Cancer Theme AstraZeneca · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A dose escalation trial to assess the safety of AZD6738 in combination with gemcitabine in participants with advanced solid tumours.

Timeline

Start
2019-10-15
Primary completion
2023-09-30
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceralasertib Small molecule 40 mg Oral
Subject Ceralasertib Small molecule 120 mg Oral
Subject Gemcitabine Small molecule 500 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous

Indications